Richard Burr: “It's been very productive so far this year, and I know all the members appreciate the leadership in addressing their…”

Where is that money gone? How is it being spent? Where is it obligated?

I oppose Ms. Kotagal's nomination and urge my colleagues to do the same.

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.

Nobody has worked harder on this issue, I think, on the Hill than I have.